» Articles » PMID: 35403414

Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument

Abstract

Rationale: It has been suggested that patients with chronic obstructive pulmonary disease (COPD) experience considerable daily respiratory symptom fluctuation. A standardized measure is needed to quantify and understand the implications of day-to-day symptom variability.

Objectives: To compare standard deviation with other statistical measures of symptom variability and identify characteristics of individuals with higher symptom variability.

Methods: Individuals in the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Exacerbations sub-study completed an Evaluating Respiratory Symptoms in COPD (E-RS) daily questionnaire. We calculated within-subject standard deviation (WS-SD) for each patient at week 0 and correlated this with measurements obtained 4 weeks later using Pearson's r and Bland Altman plots. Median WS-SD value dichotomized participants into higher versus lower variability groups. Association between WS-SD and exacerbation risk during 4 follow-up weeks was explored.

Measurements And Main Results: Diary completion rates were sufficient in 140 (68%) of 205 sub-study participants. Reproducibility (r) of the WS-SD metric from baseline to week 4 was 0.32. Higher variability participants had higher St George's Respiratory Questionnaire (SGRQ) scores (47.3 ± 20.3 versus 39.6 ± 21.5, =.04) than lower variability participants. Exploratory analyses found no relationship between symptom variability and health care resource utilization-defined exacerbations.

Conclusions: WS-SD of the E-RS can be used as a measure of symptom variability in studies of patients with COPD. Patients with higher variability have worse health-related quality of life. WS-SD should be further validated as a measure to understand the implications of symptom variability.

Citing Articles

Perspectives of Black Adults Living with Chronic Obstructive Pulmonary Disease on Barriers to Cardiovascular Disease Prevention.

Krishnan J, Murphy M, Edgar A, Aronson K, Guri A, Gross L Ann Am Thorac Soc. 2023; 21(5):706-715.

PMID: 38079490 PMC: 11109915. DOI: 10.1513/AnnalsATS.202304-342OC.


Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease.

Bhatt S, Agusti A, Bafadhel M, Christenson S, Bon J, Donaldson G Am J Respir Crit Care Med. 2023; 208(10):1026-1041.

PMID: 37560988 PMC: 10867924. DOI: 10.1164/rccm.202209-1748SO.


Discriminative Accuracy of the CAPTURE Tool for Identifying Chronic Obstructive Pulmonary Disease in US Primary Care Settings.

Martinez F, Han M, Lopez C, Murray S, Mannino D, Anderson S JAMA. 2023; 329(6):490-501.

PMID: 36786790 PMC: 9929696. DOI: 10.1001/jama.2023.0128.

References
1.
Nelsen L, Lee L, Wu W, Lin X, Murray L, Pascoe S . Reliability, validity and responsiveness of E-RS:COPD in patients with spirometric asthma-COPD overlap. Respir Res. 2019; 20(1):107. PMC: 6545030. DOI: 10.1186/s12931-019-1070-6. View

2.
Kessler R, Partridge M, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D . Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2010; 37(2):264-72. DOI: 10.1183/09031936.00051110. View

3.
Kuyucu T, Guclu S, Saylan B, Demir C, Senol T, Guner S . A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks. 2012; 59(4):328-39. DOI: 10.5578/tt.3268. View

4.
McCarley C, Hanneman S, Padhye N, Smolensky M . A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs. 2007; 9(1):8-20. DOI: 10.1177/1099800407303501. View

5.
Jones P, Lamarca R, Chuecos F, Singh D, Agusti A, Bateman E . Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014; 44(5):1156-65. DOI: 10.1183/09031936.00038814. View